Tech Company Financing Transactions
Korro Bio Funding Round
Wu Capital, Alexandria Venture Investments and Atlas Venture participated in a $91.5 million Series A funding round for Korro Bio. The round was announced on 9/11/2020.
Transaction Overview
Company Name
Announced On
9/11/2020
Transaction Type
Venture Equity
Amount
$91,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
At Korro Bio our aim is to bring transformative treatments to patients with rare and debilitating diseases by addressing the underlying genetic cause. We are utilizing the precision provided by nucleic acid-based therapeutics to target the sequences responsible within the genetic code.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Nessan Bermingham
Founder
Jean Formela
Founder
Joshua Rosenthal
Vice President
Matthew Jarpe
Vice President
Stuart Milstein
VP - Bus. Development
Yong Chang
VP - Engineering
Andrew Fraley
VP - General Counsel
Anna Barry
Browse more venture capital transactions:
Prev: 9/11/2020: Casma Therapeutics venture capital transaction
Next: 9/11/2020: Orchard venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs